Boehringer Ingelheim (Germany)

Browse company research profiles

Papers in the tracked journals with an author at Boehringer Ingelheim (Germany): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.

← Corporate research

Key findings#

From 2017 to 2026 (so far), authors at Boehringer Ingelheim (Germany) took part in 26 papers in the tracked journals, most of them in health economics and policy (13), statistics (11) and AI (2).
2 of them were published in 2025, against 1 in 2017.
Since 2023, the institutions with the most of these papers were Merck & Co., Inc., Rahway, NJ, USA (United States) (5), Uppsala University (5) and Boehringer Ingelheim (United States) (4).
The journals publishing most of them were BMC Medical Research Methodology (8), PharmacoEconomics - Open (3) and Patient (1).
The most-cited of them is “Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans” (Nature Machine Intelligence, 2021), with 1,045 citations.
Since 2023, papers in the tracked journals cited 9 of its papers 45 times; 89% of those links came from papers with a university author and 0% from its own papers.
Its own papers since 2023 cite archived papers 5 times, 60% of them papers with a company author.
Across everything OpenAlex indexes, Boehringer Ingelheim (Germany) has 10,871 works with 1,241,176 citations (h-index 410).
The tracked journals hold 21 of its 5,657 works in OpenAlex from 2017 to 2025 (0.4%).
Its main research topics in OpenAlex are Chronic Obstructive Pulmonary Disease (COPD) Research (1,180), Diabetes Treatment and Management (1,068) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (900).

Papers per year#

20172026 (so far)

Papers per publication year and category
Category	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026 (so far)
Health Economics and Policy	1	2	1	2	1	1	1	0	1	3
Statistics	0	1	0	0	2	0	0	5	1	2
AI	0	0	0	0	1	0	1	0	0	0
All categories	1	3	1	2	4	1	2	5	2	5

Where the papers come from#

Journals with the most papers, since 2023
#	Journal	Papers
1	BMC Medical Research Methodology	8
2	PharmacoEconomics - Open	3
3	Patient	1
4	Medical Image Analysis	1
5	Health and Quality of Life Outcomes	1

Institutions with the most papers, since 2023
#	Institution	Papers
1	Merck & Co., Inc., Rahway, NJ, USA (United States)	5
2	Uppsala University	5
3	Boehringer Ingelheim (United States)	4
4	Medical University of South Carolina	4
5	Amgen (United Kingdom)	3
6	Lancaster University	2
7	MRC Biostatistics Unit	2
8	RWTH Aachen University	2
9	Rensselaer Polytechnic Institute	2

Countries with the most papers, since 2023
#	Country	Papers
1	Germany	14
2	United Kingdom	10
3	United States	9
4	Sweden	5
5	France	1
6	Netherlands	1

Keywords with the most papers, since 2023
#	Keyword	Papers
1	randomization	3
2	cost-effectiveness	2
3	obesity	2
4	platform trials	2
5	treatment imbalance	2
6	EMPEROR-Preserved trial	1
7	EQ-5D-5L	1
8	French health system	1
9	Markov model	1
10	SGLT2 inhibitors	1

Most-cited papers#

Most-cited papers since 2017
#	Citations	Per month	Title	Journal	Published	Authors
1	1,045	15.4	Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans	Nature Machine Intelligence	2021-03-15	Michael Roberts, Derek Driggs, Matthew Thorpe et al.
2	109	1.0	The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review	PharmacoEconomics	2018-02-28	Alexander Diamantopoulos, Emily Wright, Katerina Vlahopoulou et al.
3	27	0.8	Learning image representations for anomaly detection: Application to discovery of histological alterations in drug development	Medical Image Analysis	2023-12-21	Igor Zingman, Birgit Stierstorfer, Charlotte Lempp et al.
4	26	0.4	Statistical inference for state occupation and transition probabilities in non-Markov multi-state models subject to both random left-truncation and right-censoring	Econometrics and Statistics	2021-10-22	Alexandra Nießl, Arthur Allignol, Jan Beyersmann et al.
5	23	0.3	Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler	Applied Health Economics and Health Policy	2019-12-06	Gustaf Ortsäter, Fredrik Borgström, Mike Baldwin et al.
6	21	0.4	A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction	The European Journal of Health Economics	2022-12-04	Ali Tafazzoli, Odette S. Reifsnider, Leana Bellanca et al.
7	13	0.2	Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China	Cost Effectiveness and Resource Allocation	2021-08-04	Mafalda Ramos, Peng Men, Xu Wang et al.
8	12	0.4	Selecting a randomization method for a multi-center clinical trial with stochastic recruitment considerations	BMC Medical Research Methodology	2024-02-28	Oleksandr Sverdlov, Yevgen V. Ryeznik, Vladimir V. Anisimov et al.
9	10	0.1	Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations	The European Journal of Health Economics	2020-04-23	Lotte Westerink, Jelmer Lennart Jens Nicolai, Carl Haakon Samuelsen et al.
10	7	0.4	Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications	Patient	2025-07-02	Trishna Bharadia, Jan Geißler, Rosie Robson et al.

Who cites its research#

Institutions whose papers cite it most, since 2023
#	Institution	Kind	Country	Links
1	University of Cambridge	University	United Kingdom	5
2	Centre National de la Recherche Scientifique	Government	France	4
3	The Alan Turing Institute	Research facility	United Kingdom	4
4	Inserm	Government	France	3
5	University of Bremen	University	Germany	3
6	Imperial College London	University	United Kingdom	3
7	Henan University of Chinese Medicine	University	China	2
8	University of California, Los Angeles	University	United States	2
9	École des Hautes Études en Santé Publique	University	France	2
10	Université de Bourgogne	University	France	2

What its papers cite#

Institutions its papers cite most, since 2023
#	Institution	Kind	Country	Links
1	Novo Nordisk (Denmark)	Company	Denmark	2
2	Health Economics and Outcomes Research (United Kingdom)	Company	United Kingdom	2
3	École Supérieure des Sciences Économiques et Commerciales	Other	France	1
4	Amgen (United States)	Company	United States	1
5	Pontificia Universidad Católica de Chile	University	Chile	1
6	William & Mary	University	United States	1
7	King's College London	University	United Kingdom	1
8	University of Bristol	University	United Kingdom	1
9	EuroQol Research Foundation	Nonprofit	Netherlands	1
10	Swedish Institute for Health Economics	Research facility	Sweden	1

Citation links inside the tracked journals; see the corporate citation network and industry–university links.

In OpenAlex#

Boehringer Ingelheim (Germany) in OpenAlex
Item	Value
Type	Company
Location	Ingelheim, Rheinland-Pfalz, Germany
Units listed in OpenAlex	27
Works in OpenAlex	10,871
Citations	1,241,176
h-index	410
i10-index	12,631
2-year mean citedness	6.80
Website	www.boehringer-ingelheim.com/de
ROR	ror.org/00q32j219
OpenAlex	openalex.org/I1330995197

Main research topics (OpenAlex, all works)
#	Topic	Field	Works
1	Chronic Obstructive Pulmonary Disease (COPD) Research	Medicine	1,180
2	Diabetes Treatment and Management	Medicine	1,068
3	Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis	Medicine	900
4	Asthma and respiratory diseases	Medicine	825
5	Inhalation and Respiratory Drug Delivery	Medicine	637

Works and citations per year in OpenAlex, and its papers in the tracked journals
Year	Works in OpenAlex	Citations received	In the tracked journals	Share
2026 (so far)	597	33,060	5	0.8%
2025	693	37,805	2	0.3%
2024	749	37,789	5	0.7%
2023	647	33,914	2	0.3%
2022	644	32,510	1	0.2%
2021	665	32,832	4	0.6%
2020	627	29,416	2	0.3%
2019	660	23,935	1	0.2%
2018	530	21,818	3	0.6%
2017	442	20,018	1	0.2%

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

Cite this page

Scholar4AI. (2026). Boehringer Ingelheim (Germany). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/boehringer-ingelheim-germany

@misc{scholar4ai-companies-boehringer-ingelheim-germany,
  author = {{Scholar4AI}},
  title = {Boehringer Ingelheim (Germany)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/boehringer-ingelheim-germany}},
  urldate = {2026-11-05},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}

Free to reuse for non-commercial purposes with attribution (CC BY-NC 4.0).